Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations. Sun S, Liu C, Duan C, Yu S, et al. J Cancer Res Clin Oncol 2023;149:2937-2949.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sun S, Liu C, Duan C, Yu S, et al. Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations. J Cancer Res Clin Oncol 2023;149:2937-2949.
PMID: 35835883